Biologics can dramatically improve quality of life for tonic patients, 'greatest work' isn't just in the arts

On July 6, after 6 years, Jay Chou released the title song MV of his 15th studio album "The Greatest Wor.

 

This song pays tribute to many great figures in the art world and their wor.

What is ankylosing spondylitis?

Ankylosing spondylitis (AS, also known as radiographically positive axial spondyloarthritis) is a type of axial spondyloarthritis (axSpA), and the other is radiologically negative axial spondyloarthritis (nr- axSp.

Ankylosing spondylitis, as the name suggests, typically invades the spine, resulting in impaired spinal mobility and varying degrees of spinal deformity, resulting in abnormal postu.

Ankylosing spondylitis affects not only the spine but also peripheral arthritis such as ankle, hip, knee, shoulder and sternoclavicular join.

To sum up, it is not suitable for patients with ankylosing spondylitis to do strenuous exerci.

 

Ankylosing spondylitis also has some extra-articular manifestations and some comorbidities , such as acute anterior uveitis, inflammatory bowel disease, psoriasis, cardiovascular disease, and lung diseas.

Application of Biologics in ASBiologics are a very important drug in the treatment of ankylosing spondylit.

1. Fast onset, can quickly relieve joint pain and swelling;

2. Inhibition of bone destruction is better than traditional disease-modifying anti-rheumatic drugs;

3. The drug is more targeted and can precisely block tumor necrosis factor, which can play a key role in the important link of pathogenes.

   
   

Indications for Biologics in Ankylosing Spondylitis

• If treatment with two or more NSAIDs for more than 4 weeks is ineffective or intolerable, switching to biologic therapy may be consider.

  
  

• For patients with obvious hip inflammation, it is generally recommended to use biological agents as soon as possib.

  
  

• Early use of biologics is also recommended for some patients with psoriasis, iritis, and inflammatory bowel disease with other complications/ comorbiditie.

  
  

TNFi

Binding of anti-TNF antibodies blocks the interaction of cytokines with cellular receptors, thereby preventing inflammation and destruction of articular cartilage and bo.

The TNFi currently available for clinical treatment of AS mainly include infliximab (IFX), adalimumab (ADA), golimumab (GOL) and etanercept (Enbrel, ET.

The usual doses of TNF inhibitors for AS and nr-axSpA are:

• Etanercept - 50 mg/week subcutaneously, 50 mg once a week or 25 mg twice a week

• Infliximab - 5 mg/kg IV infusion at weeks 0, 2, and 6, followed by a maintenance dose of 5 mg/kg every 6-8 weeks

• Adalimumab - 40 mg subcutaneously every 2 weeks

• Golimumab – 50 mg subcutaneously every 4 weeks

• Pesellizumab - 400 mg, subcutaneously administered at weeks 0, 2, and 4, followed by 200 mg every 2 weeks or 400 mg every 4 weeks

It should be noted that the following contraindications should be excluded before use of TNF inhibitors: active infection , tuberculosis, heart failure, malignancy, demyelinating disease, and allergi.

2

Anti-IL-17 monoclonal antibody

IL-17, one of the most active cytokines in AS, not only promotes bone destruction by complementing TNF-α, but also promotes bone formation at sites of inflammation or exposed to mechanical stre.

Anti-IL-17 antibodies, secukinumab, or ixekizumab are recommended for patients with contraindications to TNF inhibito.

Secukinumab was administered subcutaneously at 150 mg; the loading dose was 150 mg weekly for 4 weeks; thereafter, it was administered once every 4 wee.

For AS patients who do not respond well to 150 mg per month, especially those who have not responded well to previous TNF inhibitors, increasing the dose to 300 mg every 4 weeks may be consider.

secukinumab

This monoclonal antibody is ineffective against Crohn's disease (IBD) and may even worsen I.

Patients should be screened for latent tuberculosis before using secukinumab, and if positive, anti-tuberculosis treatment is required before using secukinum.

However, compared with TNFi, there is no report on the reactivation of latent TB after the use of secukinumab, so the use of secukinumab is the biologic agent of choice for high-risk TB patients

ixekizumab 

Like secukinumab, ixekizumab is also an anti-IL-17A monoclonal antibody marketed in EU countries and the United States, and the US FDA has approved the drug for the treatment of active AS and nr-axS.

AS patients were administered an initial subcutaneous dose of 160 mg, followed by 80 mg every 4 wee.

In nr-axSpA patients, the first dose was 80 mg, followed by 80 mg every 4 wee.

Can be used alone or in combination with conventional DMARDs such as S.

Great works are no longer high and low

The high cost of biological agents is a "luxury" that can only be used by many patients with good economic conditio.

Before being included in medical insurance, there are statistics that patients need to spend 118,800 yuan a year (the patient's condition and weight will affect the dosage of medication)

That's a lot of money for an average fami.

Take Humira of adalimumab as an examp.

The initial listing price in China was 7,600 yuan per bott.

Before the medical insurance negotiation, the pharmaceutical factory lowered the price to 3,160 yuan per bottle, but the medical insurance finally negotiated to 1,290 yuan per bott.

In Beijing, this drug is a Class B drug, and the reimbursement limit is 9
One patient only needs 473 yuan, two per month, and the annual cost is only 11,452 yuan, which is affordable for most of these patien.

Affordab.

On July 6, after 6 years, Jay Chou released the title song MV of his 15th studio album "The Greatest Wor.

For a rheumatologist, he has another identity - that is, ankylosing spondylitis (AS) patient (ps: every teacher of the editor should mention him when he talks about AS)

(ps: Every teacher of the editor should mention him when he talks about AS)

 

This song pays tribute to many great figures in the art world and their wor.

In fact, there is also a great work in the treatment of ankylosing spondylitis - biological agen.

What is ankylosing spondylitis?

What is ankylosing spondylitis?

Ankylosing spondylitis (AS, also known as radiographically positive axial spondyloarthritis) is a type of axial spondyloarthritis (axSpA), and the other is radiologically negative axial spondyloarthritis (nr- axSp.

Ankylosing spondylitis, as the name suggests, typically invades the spine, resulting in impaired spinal mobility and varying degrees of spinal deformity, resulting in abnormal postu.

Ankylosing spondylitis affects not only the spine but also peripheral arthritis such as ankle, hip, knee, shoulder and sternoclavicular join.

To sum up, it is not suitable for patients with ankylosing spondylitis to do strenuous exerci.

So there is a reason why Jay Chou doesn't do "Liu Genghong Boy ", it's not because he is la.

macro

 

Ankylosing spondylitis also has some extra-articular manifestations and some comorbidities , such as acute anterior uveitis, inflammatory bowel disease, psoriasis, cardiovascular disease, and lung diseas.

The application of combined vascular biologics in AS (the grapevine said that Jay Chou used gram)

Biologics have irreplaceable advantages for ankylosing spondylitis

Biologics have irreplaceable advantages in ankylosing spondylitis Biologics have irreplaceable advantages in ankylosing spondylitis

1. Fast onset, can quickly relieve joint pain and swelling;

2. Inhibition of bone destruction is better than traditional disease-modifying anti-rheumatic drugs;

3. The drug is more targeted and can precisely block tumor necrosis factor, which can play a key role in the important link of pathogenes.
   
   

Fast onset, can quickly relieve joint pain and swelling;

Fast onset, can quickly relieve joint pain and swelling;

Inhibition of bone destruction is better than traditional disease-modifying anti-rheumatic drugs;

Inhibition of bone destruction is better than traditional disease-modifying anti-rheumatic drugs;

The drug is more targeted and can precisely block tumor necrosis factor, which can play a key role in the important link of pathogenes.

The drug is more targeted and can precisely block tumor necrosis factor, which can play a key role in the important link of pathogenes.

precise

Indications for Biologics in Ankylosing Spondylitis

Indications for Biologics in Ankylosing Spondylitis Indications for Biologics in Ankylosing Spondylitis

• If treatment with two or more NSAIDs for more than 4 weeks is ineffective or intolerable, switching to biologic therapy may be consider.
  
  

• For patients with obvious hip inflammation, it is generally recommended to use biological agents as soon as possib.
  
  Currently , only biological agents can delay or even prevent some bone destruction and osteophyte formation
  
  Because of the high rate of disability in patients with significant hip inflammation, the benefits of early use of biologics far outweigh the risks of their u.
  
  

• Early use of biologics is also recommended for some patients with psoriasis, iritis, and inflammatory bowel disease with other complications/ comorbiditie.
  

If treatment with two or more NSAIDs for more than 4 weeks is ineffective or intolerable, switching to biologic therapy may be consider.

If treatment with two or more NSAIDs for more than 4 weeks is ineffective or intolerable, switching to biologic therapy may be consider.

For patients with obvious hip inflammation, it is generally recommended to use biological agents as soon as possib.

Currently , only biological agents can delay or even prevent some bone destruction and osteophyte formation

Because of the high rate of disability in patients with significant hip inflammation, the benefits of early use of biologics far outweigh the risks of their u.

For patients with obvious hip inflammation, it is generally recommended to use biological agents as soon as possib.

Currently , only biological agents can delay or even prevent some bone destruction and osteophyte formation

Because of the high rate of disability in patients with significant hip inflammation, the benefits of early use of biologics far outweigh the risks of their u.

Only biological agents can delay or even prevent some bone destruction and osteophyte formation

Early use of biologics is also recommended for some patients with psoriasis, iritis, and inflammatory bowel disease with other complications/ comorbiditie.

Early use of biologics is also recommended for some patients with psoriasis, iritis, and inflammatory bowel disease with other complications/ comorbiditie.

and

TNFi

TNFi

Binding of anti-TNF antibodies blocks the interaction of cytokines with cellular receptors, thereby preventing inflammation and destruction of articular cartilage and bo.

TNFi has been shown to be effective in improving lumbar lordosis in AS patien.

For most clinical patients, TNFi is the preferred type of biologic

For most clinical patients, TNFi is the preferred type of biologic

The TNFi currently available for clinical treatment of AS mainly include infliximab (IFX), adalimumab (ADA), golimumab (GOL) and etanercept (Enbrel, ET.

e.

_

The usual doses of TNF inhibitors for AS and nr-axSpA are:

• Etanercept - 50 mg/week subcutaneously, 50 mg once a week or 25 mg twice a week

• Infliximab - 5 mg/kg IV infusion at weeks 0, 2, and 6, followed by a maintenance dose of 5 mg/kg every 6-8 weeks

• Adalimumab - 40 mg subcutaneously every 2 weeks

• Golimumab – 50 mg subcutaneously every 4 weeks

• Pesellizumab - 400 mg, subcutaneously administered at weeks 0, 2, and 4, followed by 200 mg every 2 weeks or 400 mg every 4 weeks

It should be noted that the following contraindications should be excluded before use of TNF inhibitors: active infection , tuberculosis, heart failure, malignancy, demyelinating disease, and allergi.

It should be noted that the following contraindications should be excluded before use of TNF inhibitors: active infection , tuberculosis, heart failure, malignancy, demyelinating disease, and allergi.

Infect

2

2

Anti-IL-17 monoclonal antibody

Anti-IL-17 monoclonal antibody

IL-17, one of the most active cytokines in AS, not only promotes bone destruction by complementing TNF-α, but also promotes bone formation at sites of inflammation or exposed to mechanical stre.

Anti-IL-17 antibodies, secukinumab, or ixekizumab are recommended for patients with contraindications to TNF inhibito.

Anti-IL-17 antibodies, secukinumab, or ixekizumab are recommended for patients with contraindications to TNF inhibito.

Secukinumab was administered subcutaneously at 150 mg; the loading dose was 150 mg weekly for 4 weeks; thereafter, it was administered once every 4 wee.

For AS patients who do not respond well to 150 mg per month, especially those who have not responded well to previous TNF inhibitors, increasing the dose to 300 mg every 4 weeks may be consider.

secukinumab

secukinumab secukinumab

This monoclonal antibody is ineffective against Crohn's disease (IBD) and may even worsen I.

Patients should be screened for latent tuberculosis before using secukinumab, and if positive, anti-tuberculosis treatment is required before using secukinum.

However, compared with TNFi, there is no report on the reactivation of latent TB after the use of secukinumab, so the use of secukinumab is the biologic agent of choice for high-risk TB patients

Screening secukinumab is biologic of choice in high-risk TB patients

ixekizumab 

IxelizumabIxelizumab 

Like secukinumab, ixekizumab is also an anti-IL-17A monoclonal antibody marketed in EU countries and the United States, and the US FDA has approved the drug for the treatment of active AS and nr-axS.

FDA

AS patients were administered an initial subcutaneous dose of 160 mg, followed by 80 mg every 4 wee.

In nr-axSpA patients, the first dose was 80 mg, followed by 80 mg every 4 wee.

Can be used alone or in combination with conventional DMARDs such as S.

Great works are no longer high and low

Great works are also no longer high and oligostatistic ( patient condition and weight, e.

will affect the dosage of medication)

Take Humira of adalimumab as an examp.

The initial listing price in China was 7,600 yuan per bott.

Before the medical insurance negotiation, the pharmaceutical factory lowered the price to 3,160 yuan per bottle, but the medical insurance finally negotiated to 1,290 yuan per bott.

In Beijing, this drug is a Class B drug, and the reimbursement limit is 9
One patient only needs 473 yuan, two per month, and the annual cost is only 11,452 yuan, which is affordable for most of these patien.

Affordab.

leave a message here